肠系膜上动脉覆膜支架置入的中期结果
本研究回顾性分析了2014年至2019年86例因肠系膜上动脉严重粥样硬化性狭窄或闭塞接受覆膜支架治疗的患者,技术成功率97%,中位随访15.6个月,1年原发通畅率83%、2年76%,1年和2年原发辅助通畅率分别为99%和95%,再干预率14%,术后死亡均见于急性肠系膜缺血患者。
要点
- 覆膜支架治疗肠系膜上动脉闭塞性疾病中期通畅率满意,2年原发辅助通畅率达95%。
- 再干预率为14%,主要原因为支架移位、回缩、血栓形成及远端新发狭窄等。
- 术后死亡均发生于急性肠系膜缺血患者,占13%。
核心结论
- 肠系膜覆膜支架在肠系膜闭塞性疾病患者中提供非常满意的中期结果,2年原发辅助通畅率极佳,但代价是显著的再干预率。
研究设计与样本
- 回顾性分析前瞻性收集的2014年1月至2019年10月间86例因肠系膜上动脉严重粥样硬化性狭窄或闭塞接受覆膜支架治疗的患者,平均年龄70±9岁,男性57%。
主要发现
- 技术成功率为97%,共植入96枚支架,其中86枚为近端覆膜支架(Advanta V12 73枚,Lifestream 13枚)。
- 中位随访15.6个月(95%CI 15.6±3.6个月)期间,12例(14%)接受再干预。
- 1年总体原发通畅率83%(95%CI 83%±9%),原发辅助通畅率99%(95%CI 99%±3%),二次通畅率99%(95%CI 99%±3%)。
- 2年总体原发通畅率76%(95%CI 76%±13%),原发辅助通畅率95%(95%CI 95%±8%),二次通畅率95%(95%CI 95%±8%)。
- 术后死亡11例(13%),均发生于急性肠系膜缺血患者。
临床怎么用
- 对于肠系膜上动脉严重粥样硬化性狭窄或闭塞,覆膜支架可作为治疗选择,但需注意再干预风险。
- 术后应密切随访,监测支架移位、回缩、血栓及远端新发狭窄等并发症。
局限性
- 本研究为回顾性分析,样本量有限,随访时间中位数较短。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Despite the continuing controversy of covered stents (CS) vs bare metal stents, the use of CS in mesenteric occlusive disease (MOD) has been recommended by expert centers. The aim of this study was to report midterm results with CS of the superior mesenteric artery. METHODS: Between January 2014 and October 2019, patients with MOD with a severe atheromatous stenosis or occlusion of the superior mesenteric artery treated by mesenteric CS were included. Clinical presentation included both acute mesenteric ischemia (AMI), chronic mesenteric ischemia, and asymptomatic patients planned for major surgery. Demographics, procedure details, and follow-up data were prospectively collected and retrospectively reviewed. Study end points included primary patency, primary assisted patency, and secondary patency. RESULTS: During the study period, 86 patients (mean age, 70 ± 9 years; 57% males) were included. Clinical presentation was AMI (n = 42 [49%]), chronic mesenteric ischemia (n = 31 [36%]), and asymptomatic (n = 13 [15%]). The technical success rate was 97%. A total of 96 stents were implanted, including 86 proximal CS (Advanta V12, n = 73; Lifestream, n = 13). The mean length and mean diameter of the CS were 31.5 ± 6.3 mm and 6.9 ± 0.5 mm, respectively. Additional distal bare metal stents were used in 10 patients (12%) to overcome a kinking (n = 9) or a dissection (n = 1) downstream of the CS. All postoperative deaths occurred in patients with AMI (n = 11, 13%). During a median follow-up of 15.6 months (95% confidence interval [CI], 15.6 ± 3.6 months), 12 patients (14%) underwent reinterventions for either stent misplacement (n = 3), stent recoil (n = 3), stent thrombosis (n = 2), de novo stenosis at the distal edge of the CS (n = 2), or gastric ischemia (n = 1). At 1 year, overall the primary patency, primary assisted patency, and secondary patency rates were 83% (95% CI, 83% ± 9%), 99% (95% CI, 99% ± 3%), and 99% (95% CI, 99% ± 3%), respectively. At 2 years, the overall primary patency, primary assisted patency, and secondary patency rates were 76% (95% CI, 76% ± 13%), 95% (95% CI, 95% ± 8%) and 95% (95% CI, 95% ± 8%), respectively. CONCLUSIONS: Mesenteric CS provide very satisfactory midterm results in patients with MOD, with an excellent primary assisted patency rate at 2 years, at the price of a significant reintervention rate.
引用
- Girault A, Pellenc Q, Roussel A, et al. Midterm results after covered stenting of the superior mesenteric artery. J Vasc Surg. 2021. PMID: 33684478. doi:10.1016/j.jvs.2021.02.038
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。